Avanza Fonder Ab Mersana Therapeutics, Inc. Transaction History
Avanza Fonder Ab
- $3.37 Trillion
- Q4 2024
A detailed history of Avanza Fonder Ab transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Avanza Fonder Ab holds 56,298 shares of MRSN stock, worth $34,341. This represents 0.0% of its overall portfolio holdings.
Number of Shares
56,298Holding current value
$34,341% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding MRSN
# of Institutions
123Shares Held
116MCall Options Held
233KPut Options Held
457K-
Eco R1 Capital, LLC San Francisco, CA19.4MShares$11.8 Million1.59% of portfolio
-
Nextech Invest Ag12.1MShares$7.36 Million3.72% of portfolio
-
Vr Adviser, LLC New York, NY11.3MShares$6.91 Million2.22% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA8.66MShares$5.28 Million2.94% of portfolio
-
Black Rock Inc. New York, NY8.38MShares$5.11 Million0.0% of portfolio
About Mersana Therapeutics, Inc.
- Ticker MRSN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,169,296
- Market Cap $59.3M
- Description
- Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...